$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000109355717000171 Filed on August 01, 2017

Income Statement

Concept	2017 Q2	2016 Q2
Revenue	$170.6M	$137.3M
YoY Change	24.25%	47.32%
Cost Of Revenue	$53.10M	$51.80M
YoY Change	2.51%	90.44%
Gross Profit	$117.5M	$85.50M
YoY Change	37.43%	29.55%
Gross Profit Margin	68.87%	62.27%
Selling, General & Admin	$85.80M	$69.30M
YoY Change	23.81%	53.32%
% of Gross Profit	73.02%	81.05%
Research & Development	$45.30M	$36.30M
YoY Change	24.79%	48.77%
% of Gross Profit	38.55%	42.46%
Depreciation & Amortization	$3.900M	$3.900M
YoY Change	0.0%	50.0%
% of Gross Profit	3.32%	4.56%
Operating Expenses	$131.1M	$105.6M
YoY Change	24.15%	51.72%
Operating Profit	-$13.60M	-$20.10M
YoY Change	-32.34%	458.33%
Interest Expense	$3.100M	$100.0K
YoY Change	3000.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$1.800M	$0.00
YoY Change
Pretax Income	-$14.40M	-$20.10M
YoY Change	-28.36%	443.24%
Income Tax	-$17.30M	$100.0K
% Of Pretax Income
Net Earnings	$2.900M	-$20.20M
YoY Change	-114.36%	445.95%
Net Earnings / Revenue	1.7%	-14.71%
Basic Earnings Per Share	$0.03
Diluted Earnings Per Share	$0.03	-$241.6K
COMMON SHARES
Basic Shares Outstanding	86.40M shares	83.60M shares
Diluted Shares Outstanding	87.40M shares	83.60M shares

Balance Sheet

Concept	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$496.6M	$115.6M
YoY Change	329.58%	18.56%
Cash & Equivalents	$395.9M	$87.50M
Short-Term Investments	$100.7M	$28.10M
Other Short-Term Assets	$15.70M	$8.700M
YoY Change	80.46%	74.0%
Inventory	$42.80M	$42.90M
Prepaid Expenses
Receivables	$101.7M	$73.80M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$656.8M	$241.0M
YoY Change	172.53%	41.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$125.0M	$77.00M
YoY Change	62.34%	89.66%
Goodwill	$11.90M	$11.80M
YoY Change	0.85%	218.92%
Intangibles		$1.800M
YoY Change		-28.0%
Long-Term Investments
YoY Change
Other Assets	$1.900M	$1.200M
YoY Change	58.33%	140.0%
Total Long-Term Assets	$138.8M	$91.80M
YoY Change	51.2%	91.25%
TOTAL ASSETS
Total Short-Term Assets	$656.8M	$241.0M
Total Long-Term Assets	$138.8M	$91.80M
Total Assets	$795.6M	$332.8M
YoY Change	139.06%	52.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.80M	$22.40M
YoY Change	-25.0%	91.45%
Accrued Expenses	$86.80M	$50.80M
YoY Change	70.87%	73.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$105.1M	$73.90M
YoY Change	42.22%	67.19%
LONG-TERM LIABILITIES
Long-Term Debt	$327.2M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$16.30M	$12.50M
YoY Change	30.4%	420.83%
Total Long-Term Liabilities	$16.30M	$12.50M
YoY Change	30.4%	420.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$105.1M	$73.90M
Total Long-Term Liabilities	$16.30M	$12.50M
Total Liabilities	$441.9M	$86.40M
YoY Change	411.46%	81.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$660.4M	-$594.8M
YoY Change	11.03%	15.63%
Common Stock	$1.016B	$841.8M
YoY Change	20.65%	22.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$353.7M	$246.4M
YoY Change
Total Liabilities & Shareholders Equity	$795.6M	$332.8M
YoY Change	139.06%	52.38%

Cashflow Statement

Concept	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	$2.900M	-$20.20M
YoY Change	-114.36%	445.95%
Depreciation, Depletion And Amortization	$3.900M	$3.900M
YoY Change	0.0%	50.0%
Cash From Operating Activities	$14.30M	$20.10M
YoY Change	-28.86%	22.56%
INVESTING ACTIVITIES
Capital Expenditures	-$12.00M	-$10.50M
YoY Change	14.29%	66.67%
Acquisitions
YoY Change
Other Investing Activities	-$73.30M	$900.0K
YoY Change	-8244.44%	-200.0%
Cash From Investing Activities	-$85.30M	-$9.600M
YoY Change	788.54%	33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	314.4M	-700.0K
YoY Change	-45014.29%	-116.28%
NET CHANGE
Cash From Operating Activities	14.30M	20.10M
Cash From Investing Activities	-85.30M	-9.600M
Cash From Financing Activities	314.4M	-700.0K
Net Change In Cash	243.4M	9.800M
YoY Change	2383.67%	-27.41%
FREE CASH FLOW
Cash From Operating Activities	$14.30M	$20.10M
Capital Expenditures	-$12.00M	-$10.50M
Free Cash Flow	$26.30M	$30.60M
YoY Change	-14.05%	34.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86560946	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
	dei	Trading Symbol TradingSymbol	DXCM
CY2016Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	4500000	USD
CY2017Q2	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	13600000	USD
	dxcm	Acquisitionrelatedholdbackliability Acquisitionrelatedholdbackliability	1800000	USD
	dxcm	Acquisitionrelatedholdbackliability Acquisitionrelatedholdbackliability	0	USD
	dxcm	Capitalized Costs And Financing Liability CapitalizedCostsAndFinancingLiability	6000000	USD
	dxcm	Capitalized Costs And Financing Liability CapitalizedCostsAndFinancingLiability	0	USD
CY2016Q4	dxcm	Clinical Trials ClinicalTrials	1100000	USD
CY2017Q2	dxcm	Clinical Trials ClinicalTrials	300000	USD
CY2017Q2	dxcm	Fair Value Assets Level3 Transfers Amount FairValueAssetsLevel3TransfersAmount	0	USD
CY2016Q4	dxcm	Financing Lease Obligation FinancingLeaseObligation	6700000	USD
CY2017Q2	dxcm	Financing Lease Obligation FinancingLeaseObligation	6700000	USD
CY2016Q4	dxcm	Pharmacy Rebates PharmacyRebates	8200000	USD
CY2017Q2	dxcm	Pharmacy Rebates PharmacyRebates	13000000	USD
	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
	dxcm	Revenue Recognition Sales Returns Coverage Period RevenueRecognitionSalesReturnsCoveragePeriod	P30D
CY2016Q2	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	7300000	USD
	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	13500000	USD
CY2017Q2	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	3400000	USD
	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	8400000	USD
CY2017Q2	dxcm	Working Capital WorkingCapital	551700000	USD
CY2016Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	68100000	USD
CY2017Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	72200000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	24500000	USD
CY2017Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	16800000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-500000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-200000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	101700000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	101700000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47200000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	48700000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1600000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	905700000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1015600000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2100000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4900000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7400000	shares
CY2016Q4	us-gaap	Assets Assets	402800000	USD
CY2017Q2	us-gaap	Assets Assets	795600000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	280000000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	656800000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	29200000	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	100700000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	29200000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	100700000	USD
CY2017Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	83500000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29200000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	100700000	USD
CY2017Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	17200000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86100000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87500000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94500000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	395900000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1400000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	301400000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	496600000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	32300000	USD
CY2017Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	349100000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84900000	shares
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	500000	USD
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86800000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84600000	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86500000	shares
CY2016Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2017Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20600000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39800000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2600000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39400000	USD
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2017Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	320500000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	51800000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	92900000	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	53100000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	101300000	USD
CY2016Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	0	USD
CY2017Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P6M
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	70700000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	17100000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-17100000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7300000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8900000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	900000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7600000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-200000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1200000	USD
CY2016Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.201
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	33400000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31400000	USD
CY2017Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	11300000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	11900000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	85500000	USD
	us-gaap	Gross Profit GrossProfit	160600000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	117500000	USD
	us-gaap	Gross Profit GrossProfit	211600000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17300000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15900000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20100000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39300000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14400000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54700000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9300000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1700000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2100000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7200000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2800000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	900000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1500000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2700000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6200000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	100000	USD
	us-gaap	Interest Expense InterestExpense	200000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	3100000	USD
	us-gaap	Interest Expense InterestExpense	3600000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	23000000	USD
CY2017Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	22400000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	45400000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	42800000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20100000	USD
CY2017Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16300000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2300000	USD
CY2017Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4100000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	500000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	700000	USD
CY2016Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2300000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4200000	USD
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2800000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5600000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	119000000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	441900000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	402800000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	795600000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	102400000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	105100000	USD
CY2017Q2	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	200000000	USD
CY2017Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2017Q2	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2016Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	0	USD
CY2017Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	409700000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2500000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	394700000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20800000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-106700000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19900000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14600000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-20200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39400000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	2900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-38800000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	3800000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4900000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	105600000	USD
	us-gaap	Operating Expenses OperatingExpenses	199900000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	131100000	USD
	us-gaap	Operating Expenses OperatingExpenses	265600000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20100000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39300000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13600000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54000000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	60600000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	11500000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	11200000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	10800000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	9900000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	13000000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4200000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20000000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20200000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2100000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1900000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4900000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4100000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-400000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-400000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-300000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-600000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16600000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16300000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	6100000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1800000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2200000	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2600000	USD
CY2017Q2	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	700000	USD
	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	-400000	USD
	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	0	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-3600000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	20900000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	91400000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34900000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9200000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15700000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	389000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4800000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5700000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	75000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	75000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	21700000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	19600000	USD
CY2016Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	5100000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	8900000	USD
CY2017Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	5000000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	9900000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	156600000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	173700000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109400000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	125000000	USD
CY2017Q2	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	70700000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2300000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-621000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	75000000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36300000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68500000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45300000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93400000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-660400000	USD
CY2016Q2	us-gaap	Revenues Revenues	137300000	USD
	us-gaap	Revenues Revenues	253500000	USD
CY2017Q2	us-gaap	Revenues Revenues	170600000	USD
	us-gaap	Revenues Revenues	312900000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	69300000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	131400000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	85800000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	172200000	USD
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	27600000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	52700000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	25300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	55900000	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	3300000	USD
CY2016Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	5700000	USD
CY2016Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	7900000	USD
CY2016Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9800000	USD
CY2017Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9900000	USD
CY2017Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	8300000	USD
	us-gaap	Stock Issued1 StockIssued1	7200000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	283800000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	353700000	USD
CY2016Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0	USD
CY2017Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	8800000	USD
CY2016Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1000000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82800000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85800000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82800000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86400000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85800000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, convertible debt, employee bonus, clinical trial expenses, allowance for bad debt and refunds and rebates, including pharmacy rebates. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-17-000171-index-headers.html	Edgar Link	pending
0001093557-17-000171-index.html	Edgar Link	pending
0001093557-17-000171.txt	Edgar Link	pending
0001093557-17-000171-xbrl.zip	Edgar Link	pending
a42838951finala201200_image1.jpg	Edgar Link	pending
dxcm-20170630.xml	Edgar Link	completed
dxcm-20170630.xsd	Edgar Link	pending
dxcm-20170630_cal.xml	Edgar Link	unprocessable
dxcm-20170630_def.xml	Edgar Link	unprocessable
dxcm-20170630_lab.xml	Edgar Link	unprocessable
dxcm-20170630_pre.xml	Edgar Link	unprocessable
dxcm-63017x10q.htm	Edgar Link	pending
dxcm06302017ex1047.htm	Edgar Link	pending
dxcm6302017exhibit1042.htm	Edgar Link	pending
dxcm6302017exhibit1043.htm	Edgar Link	pending
dxcm6302017exhibit1046.htm	Edgar Link	pending
dxcm6302017exhibit31.htm	Edgar Link	pending
dxcm6302017exhibit3101.htm	Edgar Link	pending
dxcm6302017exhibit3102.htm	Edgar Link	pending
dxcm6302017exhibit3201.htm	Edgar Link	pending
dxcm6302017exhibit3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g396725cm-6.jpg	Edgar Link	pending
g396725cm-6nn.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2017 Q2 Form 10-Q Financial Statement

#000109355717000171 Filed on August 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2017 Q2 Form 10-Q Financial Statement

#000109355717000171 Filed on August 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm